D

Devyser Diagnostics AB
STO:DVYSR

Watchlist Manager
Devyser Diagnostics AB
STO:DVYSR
Watchlist
Price: 129 SEK -1.9% Market Closed
Market Cap: 2.1B SEK
Have any thoughts about
Devyser Diagnostics AB?
Write Note

Devyser Diagnostics AB
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Devyser Diagnostics AB
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
D
Devyser Diagnostics AB
STO:DVYSR
Cash from Operating Activities
-kr69.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Cash from Operating Activities
kr426m
CAGR 3-Years
24%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Cash from Operating Activities
kr5.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Cash from Operating Activities
kr811m
CAGR 3-Years
13%
CAGR 5-Years
15%
CAGR 10-Years
19%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Cash from Operating Activities
kr6.7B
CAGR 3-Years
18%
CAGR 5-Years
16%
CAGR 10-Years
40%
BioArctic AB
STO:BIOA B
Cash from Operating Activities
kr309.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Devyser Diagnostics AB
Glance View

Market Cap
2.1B SEK
Industry
Biotechnology

Devyser Diagnostics AB engages in the development, manufacture and sale of kits for genetic testing in routine diagnostics. The company is headquartered in Hagersten, Stockholm. The company went IPO on 2021-12-10. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The firm has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The firm provides its products in more than 45 countries.

DVYSR Intrinsic Value
124.21 SEK
Overvaluation 4%
Intrinsic Value
Price
D

See Also

What is Devyser Diagnostics AB's Cash from Operating Activities?
Cash from Operating Activities
-69.7m SEK

Based on the financial report for Dec 31, 2023, Devyser Diagnostics AB's Cash from Operating Activities amounts to -69.7m SEK.

What is Devyser Diagnostics AB's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 1Y
-72%

Over the last year, the Cash from Operating Activities growth was -72%.

Back to Top